Adagene (ADAG) Competitors $1.90 +0.02 (+1.28%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAG vs. ARCT, MBX, CMPX, TERN, HUMA, PRTA, HRTX, AMRN, PRME, and SNDLShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Arcturus Therapeutics (ARCT), MBX Biosciences (MBX), Compass Therapeutics (CMPX), Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Its Competitors Arcturus Therapeutics MBX Biosciences Compass Therapeutics Terns Pharmaceuticals Humacyte Prothena Heron Therapeutics Amarin Prime Medicine SNDL Adagene (NASDAQ:ADAG) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Does the media favor ADAG or ARCT? In the previous week, Arcturus Therapeutics had 1 more articles in the media than Adagene. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 4 mentions for Adagene. Arcturus Therapeutics' average media sentiment score of 0.46 beat Adagene's score of 0.32 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in ADAG or ARCT? 9.5% of Adagene shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, ADAG or ARCT? Adagene has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Which has preferable earnings & valuation, ADAG or ARCT? Adagene has higher earnings, but lower revenue than Arcturus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K913.93-$33.42MN/AN/AArcturus Therapeutics$152.31M2.58-$80.94M-$2.53-5.72 Is ADAG or ARCT more profitable? Adagene has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Adagene's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Arcturus Therapeutics -47.47%-27.41%-19.01% Do analysts prefer ADAG or ARCT? Adagene currently has a consensus price target of $8.00, indicating a potential upside of 312.37%. Arcturus Therapeutics has a consensus price target of $54.00, indicating a potential upside of 272.93%. Given Adagene's higher possible upside, equities research analysts clearly believe Adagene is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryArcturus Therapeutics beats Adagene on 8 of the 15 factors compared between the two stocks. Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdageneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.57M$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E RatioN/A8.0519.5820.23Price / Sales913.93296.11442.27127.79Price / CashN/A42.7337.5058.41Price / Book1.707.748.085.60Net Income-$33.42M-$54.96M$3.16B$248.43M7 Day Performance2.92%6.04%3.77%5.15%1 Month Performance-1.02%4.47%3.90%7.62%1 Year Performance-29.71%6.12%34.22%21.56% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.0509 of 5 stars$1.94+3.2%$8.00+312.4%-31.6%$88.57M$100K0.00260Gap UpARCTArcturus Therapeutics2.6893 of 5 stars$13.01-2.4%$53.50+311.2%-34.2%$361.52M$152.31M-5.14180MBXMBX Biosciences2.55 of 5 stars$11.41+6.1%$37.50+228.7%N/A$359.31MN/A0.0036CMPXCompass Therapeutics2.6547 of 5 stars$2.60+1.6%$13.13+404.8%+216.4%$354M$850K-6.3420TERNTerns Pharmaceuticals3.7656 of 5 stars$3.73-2.6%$15.63+318.9%-34.4%$334.50MN/A-3.4240HUMAHumacyte2.907 of 5 stars$2.09-1.4%$11.71+460.5%-56.6%$328.85M$1.57M-3.03150News CoverageAnalyst ForecastPRTAProthena3.0657 of 5 stars$6.07-0.2%$31.50+418.9%-68.1%$327.27M$135.16M-2.92130HRTXHeron Therapeutics3.9299 of 5 stars$2.07-3.3%$5.00+141.5%-24.0%$326.49M$144.29M-34.50300News CoverageAMRNAmarin0.7096 of 5 stars$16.22+3.2%$12.00-26.0%+23.8%$325.31M$228.61M-4.46360High Trading VolumePRMEPrime Medicine4.0811 of 5 stars$2.47+2.1%$10.08+308.2%-19.2%$324.30M$3.85M-1.20234Positive NewsOptions VolumeHigh Trading VolumeSNDLSNDL3.6638 of 5 stars$1.21-1.6%$3.63+199.6%-27.9%$323.21M$671.81M-4.172,516News CoverageGap Down Related Companies and Tools Related Companies ARCT Competitors MBX Competitors CMPX Competitors TERN Competitors HUMA Competitors PRTA Competitors HRTX Competitors AMRN Competitors PRME Competitors SNDL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAG) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAG Stock Alerts